Meta-analysis of GLP-1 agonists for Parkinson's disease motor symptoms shows limited benefit
A recent review found no clear benefit for Parkinsons disease patients taking GLP-1 drugs compared to placebo
This meta-analysis of randomized trials examined GLP-1 receptor agonists for Parkinson's disease. It found no statistically significant impr…
A new analysis of studies shows GLP-1 drugs did not improve movement or daily life for people with Parkinsons disease. While quality of life…
Meta-analysis finds GLP-1RA plus SGLT2i reduces UACR in type 2 diabetes with kidney disease
Combining two diabetes drugs protects kidneys better than using just one alone
This systematic review and meta-analysis of 1974 adults with type 2 diabetes and diabetic kidney disease found that combination therapy with…
Combining two common diabetes drugs offers better kidney protection than taking just one alone for people with type 2 diabetes
Narrative review discusses pharmacological and lifestyle interventions for type 2 diabetes and psychological health
New hope for diabetes patients struggling with anxiety and depression
This narrative review examines the relationship between type 2 diabetes and conditions such as anxiety, depression, and cognitive impairment…
Diabetes drugs that control blood sugar might also help improve mood and reduce anxiety for patients living with the condition.
Narrative review examines multidisciplinary strategies for metabolic syndrome in bipolar disorder
Half of Bipolar Patients Face Hidden Heart Risks
This narrative review explores multidisciplinary monitoring and treatment strategies, including lifestyle and pharmacological approaches, fo…
Imagine living with bipolar disorder. You manage your mood swings with medication and therapy.
GLP-1 receptor agonists associated with lower mortality in HFrEF on GDMT
Heart Failure Patients Cut Death Risk With Common Diabetes Drug
In a retrospective, multicenter cohort study of 1,518 adults with HFrEF on guideline-directed therapy, GLP-1 receptor agonist use was associ…
Adding a common diabetes medication to standard heart failure treatment may significantly lower death rates.
Monitoring report on US GLP-1 RA prescribing trends shows increased oral semaglutide use
Why are so many people getting new diabetes and weight-loss drugs?
This monitoring report analyzes real-world US electronic health record data from Truveta on GLP-1 RA prescribing.
Prescriptions for diabetes and weight-loss drugs jumped sharply in the US after a new oral pill was approved, with first-time use rising ove…
Narrative review conceptualizes CVD as systemic immune–metabolic–inflammatory disease
Review suggests immune and metabolic factors drive cardiovascular disease progression
This narrative review synthesizes evidence on cardiovascular disease as a systemic immune–metabolic–inflammatory condition.
Immune and metabolic factors actively drive heart disease progression, offering new ways to assess risk and tailor prevention strategies.
Network meta-analysis finds metabolic surgery superior to GLP-1 agonists for weight loss in obesity
Weight-Loss Surgery Still Leads, But a New Medication Closes the Gap
A network meta-analysis of 20,015 adults with overweight or obesity compared metabolic/bariatric surgery, GLP-1 receptor agonists, and lifes…
Weight-loss surgery still beats drugs overall, but the newest medication tirzepatide closes the gap enough to matter for people who can't ha…
GLP-1 agents and cognitive interventions address obesity and eating disorders via appetite and gut-brain signaling pathways
Why Your Brain Craves Donuts More Than Broccoli
This narrative review examines the cognitive and neural foundations of food preference and reward processing in obesity and eating disorders…
Your brain decides what foods you crave long before your stomach gets a vote, and scientists are finally learning how to rewrite that decisi…
Network meta-analysis of novel antidiabetic drugs in T2DM with CKD shows sotagliflozin, empagliflozin, and semaglutide rank highest for cardiovascular and renal outcomes
A Clear Winner Emerges for Diabetes Patients with Kidney Disease
This network meta-analysis evaluated novel antidiabetic drugs, including SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors, i…
For millions managing both diabetes and kidney disease, new research clarifies which medications offer the best protection for their heart a…
Narrative review assesses GLP-1 receptor agonists versus insulin for steroid-induced hyperglycemia and diabetes
A Common Medication Side Effect May Have a Surprising New Solution
This narrative review evaluates the efficacy and safety of glucocorticosteroid-induced hyperglycemia (SIH) and steroid-induced diabetes (SID…
Doctors are exploring a new way to protect patients from the dangerous blood sugar spikes caused by essential steroid medications.
HFpEF probability scores rule out disease but show limitations in AF and obesity phenotypes
HFpEF probability scores work well for typical cases but struggle with atrial fibrillation and obesity
This systematic review evaluated the performance of HFpEF probability scores (HFA-PEFF and H2FPEF) in patients with heart failure with prese…
Heart failure scores work well for typical cases but lose accuracy in patients with atrial fibrillation or obesity due to altered biological…